AbCellera Biologics Inc
(NAS:ABCL)
$
2.995
0.045 (1.53%)
Market Cap: 871.33 Mil
Enterprise Value: 299.59 Mil
PE Ratio: 0
PB Ratio: 0.81
GF Score: 66/100 Abcellera Biologics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023 / 08:20PM GMT
Release Date Price:
$7.47
(+0.95%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst
Perfect. Well, thank you, everyone, for joining us this afternoon to speak with AbCellera, CEO, Carl Hansen. Thank you so much for joining us.
Carl L.G. Hansen
AbCellera Biologics Inc. - CEO, President & Chairperson
Thanks, Andrea. Great to be here.
Questions & Answers
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst
So maybe to start, AbCellera, a company that's positioned at the intersection of biotech and tech, which is hot right now. But maybe for some of -- some of the people in the crowd who may be less familiar with your company, maybe describe your business thesis here and how that really helps fit you into the drug discovery and development process.
Carl L.G. Hansen
AbCellera Biologics Inc. - CEO, President & Chairperson
Great. Sure, happy to. So AbCellera was founded a little over 10 years ago. And the business thesis was essentially
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot